OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider," said Michael J. O'Brien, Beardsworth President and CEO. "OmniComm's solid reputation, early adoption of industry standards, and the many features and benefits the platform offers, made it a logical choice."
OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC utilizing OmniComm's native, template matching, subsystem. Electronic exports from TrialMaster EDC to Beardsworth's BNet portal will be achieved utilizing OmniComm's new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet.
"We look forward to working with Beardsworth on their next study and welcome them to our very successful CRO preferred program," remarked Stephen Johnson, COO of OmniComm Systems. "We are pleased that OmniComm's electronic data capture solution, TrialMaster, was chosen to capture and process the clinical trial data of this exciting vaccine study. TrialMaster will enable Beardsworth to confidently offer their clients an extensible, eClinical solution that will complement the outstanding services which have made their company a success."
HPV vaccine linked to significant decline in cervical cancer mortality